Sowell Financial Services LLC Purchases 40,735 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Sowell Financial Services initiated a position in Kiniksa Pharmaceuticals International, purchasing 40,735 shares valued at approximately $3.04 million. Institutional investors collectively own 53.95% of KNSA.
• Analyst sentiment remains positive, with eight analysts rating the stock a Buy and one issuing a Hold. The consensus price target is $93.14, while several firms recently raised their targets to between $90 and $100.
• KNSA shares opened at $79.70, near their 52-week high of $84.06. In its latest quarter, Kiniksa reported earnings of $0.30 per share and revenue of $243.6 million, exceeding revenue expectations.

Sowell Financial Services LLC purchased a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 40,735 shares of the company's stock, valued at approximately $3,039,000. Sowell Financial Services LLC owned approximately 0.05% of Kiniksa Pharmaceuticals International at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Allworth Financial LP boosted its holdings in Kiniksa Pharmaceuticals International by 42.0% in the 2nd quarter. Allworth Financial LP now owns 453 shares of the company's stock worth $29,000 after acquiring an additional 134 shares during the period. KBC Group NV acquired a new stake in Kiniksa Pharmaceuticals International in the first quarter valued at approximately $34,000. Nykredit A S purchased a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter valued at approximately $34,000. USA Financial Formulas purchased a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter valued at approximately $69,000. Finally, GAMMA Investing LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 21.1% during the third quarter. GAMMA Investing LLC now owns 1,278 shares of the company's stock valued at $95,000 after purchasing an additional 223 shares during the period. 53.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on KNSA. Canaccord Genuity Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a "buy" rating in a research report on Wednesday, July 29th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 30th. Citigroup raised their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday, October 8th. Finally, The Goldman Sachs Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $93.14.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA opened at $79.70 on Thursday. The company has a market capitalization of $6.22 billion, a P/E ratio of 82.16 and a beta of 0.04. Kiniksa Pharmaceuticals International, plc has a one year low of $35.20 and a one year high of $84.06. The stock has a 50-day moving average price of $78.07 and a 200 day moving average price of $64.76.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, meeting analysts' consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. The firm had revenue of $243.60 million during the quarter, compared to analyst estimates of $226.49 million. As a group, equities research analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, CAO Michael Megna sold 4,600 shares of the company's stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total value of $369,380.00. Following the transaction, the chief accounting officer directly owned 29,062 shares of the company's stock, valued at $2,333,678.60. This represents a 13.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total value of $299,092.39. Following the transaction, the director owned 11,672 shares of the company's stock, valued at approximately $950,450.96. This trade represents a 23.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 51.98% of the company's stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.